Do HER2 low tumors have a distinct clinicopathologic phenotype?

Authors

null

Natália Polidorio

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Natália Polidorio , Srinivasa Sevilimedu Veeravalli , Giacomo Montagna , Tiana Le , Monica Morrow

Organizations

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, New York, NY

Research Funding

Institutional Funding
Memorial Sloan Kettering Cancer Center

Background: Clinicopathologic features of breast cancer subtypes defined by hormone receptor (HR) and HER2 status differ. These analyses classified HER2 IHC <3+ with negative FISH as HER2-. With the recognition of the clinical relevance of HER2 low, there is debate as to whether this is a distinct subtype. We sought to determine if features of HER2 low tumors differ from HER2- and HER2+ after controlling for HR status. Methods: Patients undergoing upfront surgery from 1998 to 2010 were identified from a prospectively maintained institutional database. HER2 status was classified by IHC/FISH analysis as HER2-, HER2 low (IHC 1+ or 2+ with negative FISH), and HER2+ (IHC 3+ or FISH +) and stratified by HR status. Univariable (UVA) and multivariable multinomial logistic regression analysis (MVA) were performed to determine associations among variables and subtypes. Results: 11,323 tumors from 11,072 patients were included. 5,104 (45%) were HER2 low, 41.2% were HER2- and 13.6% were HER2+. On MVA stratified by HER2 status only, compared to HER2- tumors, HER2 low was associated with LVI (OR 1.2 [95% CI 1.06-1.36]; p=.003), multifocality (OR 1.26 [95% CI, 1.12-1.42]; p<.001), nodal micrometastasis (OR 1.15 [95% CI, 1.02-1.31]; p=.024), and lower rates of <3 positive nodes (OR 0.77 [95% CI, 0.66-0.90], p=.001). HER2+ was associated with younger age, high grade, multifocality, extensive intraductal component (EIC), and pN2/3 nodal stage. Clinicopathologic features stratified by HR and HER2 status are shown in the table. On UVA, in both HR+ and HR– tumors, age and multifocality were associated with HER2 low, and LVI, multifocality, and EIC with HER2+ compared to HER2- tumors. On MVA, no variables were independently associated with both HR+ and HR-/HER2 low tumors compared to HER2-. In contrast, HER2+ tumors regardless of HR status were significantly associated with multifocality and EIC. Conclusions: HER2 low breast cancer features seem to be driven by HR status and HER2 overexpression. We do not have enough evidence to support the interpretation of HER2 low as a distinct subtype.

Clinicopathologic features by HR/HER2 status.

Characteristic
n (%)
HR +HR -
HER2-HER2 lowpHER2+pHER2-HER2 lowpHER2+p
3,8074,5961,007862508543
Median age (IQR)58 (48, 68)57 (47, 66)<0.0151 (43, 61)<0.0153 (43, 63)55 (46, 65)<0.0153 (45, 61)>0.9
LVI968 (25)1,380 (30)<0.01440 (44)<0.01277 (32)173 (34)0.5238 (44)<0.01
High grade1,666 (46)2,269 (51)<0.01815 (83)<0.01765 (93)451 (90)0.14506 (94)0.2
Multifocal961 (25)1,334 (29)<0.01327 (33)<0.01156 (18)120 (24)0.01200 (37)<0.01
EIC347 (15)509 (16)0.2171 (24)<0.0145 (8.5)50 (14)<0.01104 (30)<0.01
Nodal disease
02,304 (61)2,814 (61)401 (40)463 (54)270 (53)251 (46)
Mic126 (3.3)221 (4.8)<0.0134 (3.4)0.0215 (1.7)17 (3.4)0.0617 (3.1)0.04
1-2+668 (18)773 (17)0.4113 (11)0.8130 (15)74 (15)0.9105 (19)<0.01
≥ 3+682 (18)778 (17)0.3455 (45)<0.01250 (29)145 (29)>0.9168 (31)0.09

p values from multinomial UVA.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 570)

DOI

10.1200/JCO.2023.41.16_suppl.570

Abstract #

570

Poster Bd #

400

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Annual Meeting

HER2 alterations and prognostic implications in all subtypes of breast cancer.

First Author: Kaitlyn O'Keefe

Abstract

2023 ASCO Annual Meeting

De novo metastatic Her2+ breast cancer in a diverse population of women under age 40.

First Author: Victoria Chung

Abstract

2023 ASCO Annual Meeting

De-escalating therapy dilemma in small HER2 positive node negative breast cancer.

First Author: Nawale Hajjaji